Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban versus warfarin for prevention of stroke and systemic embolism in atrial fibrillation
ACTRN12609000026224Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Apixaban arm with Warfarin arm (2 arms). Primary endpoint: Noninferiority of apixaban versus warfarin for stroke or systemic embolism. Started Apr 2007; status: recruiting.
02
Drugs
apixabanwarfarin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ACTRN12609000026224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000026224.